17 alpha-hydroxylase deficiency surgery

Congenital adrenal hyperplasia main page
17 alpha-hydroxylase deficiency Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating 17 alpha-hydroxylase deficiency from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
CT
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
17 alpha-hydroxylase deficiency surgery On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of 17 alpha-hydroxylase deficiency surgery All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on 17 alpha-hydroxylase deficiency surgery
CDC on 17 alpha-hydroxylase deficiency surgery
17 alpha-hydroxylase deficiency surgery in the news
Blogs on 17 alpha-hydroxylase deficiency surgery
Directions to Hospitals Treating Congenital adrenal hyperplasia due to 17 alpha-hydroxylase deficiency
Risk calculators and risk factors for 17 alpha-hydroxylase deficiency surgery

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mehrian Jafarizade, M.D [2]

Overview

The predominant therapy for ambigous genitalia in to 17 alpha-hydroxylase deficiency is surgical correction.

Surgery

Affected 46,XY patients require gonadectomy to prevent malignant degeneration of testes. The reconstruction surgery for ambiguous genitalia in genetically male patients may be applied.